Ghasemzadeh A

No ORCID on file · 7 papers in corpus · active 2019-2026

Study types

  • other 1

Condition tags

  • dysmenorrhea 1
  • endometriosis 1
  • endometrioma 1
  • dyspareunia 1
2026
Scientific reports ·doi:10.1038/s41598-026-38941-6

Introduction Approximately 1-5% of pregnant women experience recurrent pregnancy loss (RPL). Early detection and evaluation of high-risk variables allow for the initiation of recommended treatments while also reducing the likelihood of RPL …

2025
Clinical and experimental reproductive medicine ·doi:10.5653/cerm.2024.07129

ObjectiveFor successful embryo implantation in women with high pulsatility, uterine vascular resistance and pulsatility must be reduced. We examined the effects of amlodipine on uterine pulsatility index (PI), resistance index (RI), and emb…

2025
Galen medical journal ·doi:10.31661/gmj.v14i.3840

BackgroundBackground: Infertility is a global public health concern, and controlled ovarian stimulation (COS) plays a crucial role in assisted reproductive technologies (ART) by facilitating the retrieval of multiple oocytes. This single-bl…

2025
Scientific reports ·doi:10.1038/s41598-025-27561-1

Despite advancements in assisted reproductive technology (ART), recurrent implantation failure (RIF) continues to pose a significant challenge to achieving pregnancy. We included 2,463 retrospective RIF patients with no gynecological and an…

other 2023
Clinics (Sao Paulo, Brazil) ·doi:10.1016/j.clinsp.2023.100224

BACKGROUND: Endometriosis is a chronic inflammatory disease affecting about 10% of women of reproductive age. Endometrioma is the most common presentation of endometriosis in ovaries. OBJECTIVES: Herein, the authors study the effect of the…

2022
International journal of fertility & sterility ·doi:10.22074/ijfs.2022.541389.1210

BackgroundGrowth hormone (GH) is a potential treatment in the assisted reproductive technology (ART) to improve endometrial receptivity and thickness. In the current study, we investigated the effect of the intrauterine administration of GH…

2019
International journal of reproductive biomedicine ·doi:10.18502/ijrm.v18i1.6197

BackgroundOral progesterone is recommended as an alternative to gonadotropin-releasing hormone (GnRH) agonists and antagonists to prevent luteinizing hormone (LH) surge in assisted reproductive technology (ART) cycles. However, there are li…